Research on Sacituzumab Tirumotecan for Lung Cancer Published

Translational research findings regarding sacituzumab tirumotecan (sac-TMT) combined with osimertinib for advanced EGFR-mutant non-small cell lung cancer (NSCLC) have been published. The study, featured in *Cancer Cell*, suggests that this combination may delay drug resistance by inducing TROP2 upregulation in drug-tolerant cells. This provides a mechanistic basis for the treatment strategy.